Vomiting
📧 Sign up to get email alerts when something new happens for Vomiting.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-25EMA Authorised: Akynzeo (netupitant;palonosetron hydrochloride) — Helsinn Birex Pharmaceuticals Ltd
The EMA authorised Akynzeo (netupitant and palonosetron hydrochloride) for vomiting, nausea, cancer-related indications.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting [Phase 3]
Phase 3 clinical trial evaluating olanzapine plus metoclopramide to prevent opioid-induced nausea and vomiting is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use [Phase 3]
Phase 3 study evaluating Tradipitant for nausea and vomiting induced by GLP-1 receptor agonist use in obesity is currently recruiting.
-
FDA approval · 2026-04-01FDA Approved: PROCHLORPERAZINE EDISYLATE — Supplemental Application (Somerset Therapeutics, LLC)
FDA approved a supplemental application for PROCHLORPERAZINE EDISYLATE (ANDA212257) filed by Somerset Therapeutics, LLC. This approval relat…
-
CLINICAL_TRIALS research · 2025-10-08Clinical Trial Update: Inhaled Isopropyl Alcohol for Treatment of Nausea [Phase 2, Phase 3]
Clinical trial evaluating inhaled isopropyl alcohol for nausea and vomiting is in Phase 2/3 and currently recruiting, with enrollment limite…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: The Effect of a Protective Oral Care Protocol Using Peppermint Oil Mouthwash [NA]
An update on a clinical trial evaluating a protective oral care protocol using peppermint oil mouthwash for patients with hematologic neopla…
-
FDA approval · 2025-09-08FDA Approved: PROCHLORPERAZINE MALEATE — Original Application (Aurobindo Pharma Limited)
The FDA approved Aurobindo Pharma Limited's original ANDA for prochlorperazine maleate, allowing the generic antiemetic/antipsychotic to be …
-
FDA approval · 2025-06-24FDA Approved: PROMETHAZINE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for promethazine hydrochloride from Hikma Pharmaceuticals USA, confirming the approval of a generic …
-
FDA approval · 2025-01-22FDA Approved: PROCHLORPERAZINE MALEATE — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved a supplemental application for PROCHLORPERAZINE MALEATE by Ajanta Pharma USA Inc. under the ANDA pathway.
-
FDA approval · 2024-09-13FDA Approved: PROCHLORPERAZINE EDISYLATE — Original Application (Somerset Therapeutics, LLC)
FDA approved the original ANDA for Prochlorperazine Edisylate from Somerset Therapeutics, LLC, authorizing its marketing as an antiemetic fo…
-
CLINICAL_TRIALS trial_result · 2023-06-01Clinical Trial Update: Haloperidol for the Treatment of Nausea and Vomiting in the ED [Phase 4]
Phase 4 trial update evaluating haloperidol for nausea and vomiting in the emergency department has completed.
-
FDA approval · 2023-05-01FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Onesource Specialty Pharma Limited)
The FDA approved a supplemental application for ondansetron hydrochloride from Onesource Specialty Pharma Limited, approving this generic an…
-
FDA approval · 2023-04-04FDA Approved: PROCHLORPERAZINE MALEATE — Original Application (Bionpharma Inc.)
FDA approved an Original Application for Prochlorperazine Maleate from Bionpharma Inc., authorizing its marketing as a generic antiemetic.
-
CLINICAL_TRIALS trial_result · 2023-03-22Clinical Trial Update: A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV [Phase 3]
A Phase 3 clinical trial evaluating CL-108 5 mg for acute pain and prevention of opioid-induced nausea/vomiting has completed with posted re…
-
FDA approval · 2023-03-17FDA Approved: PROCHLORPERAZINE MALEATE — Original Application (GLENMARK PHARMACEUTICALS INC., USA)
FDA approved Prochlorperazine maleate from Glenmark Pharmaceuticals under an Original Application; it is an antiemetic indicated to prevent …
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: Hyoscine Butyl-bromide Versus Ondansetron for Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia [Phase 4]
Phase 4 trial comparing hyoscine butyl-bromide to ondansetron for vomiting during cesarean section under spinal anesthesia has completed.
-
EMA approval · 2023-02-24EMA Authorised: Aloxi (palonosetron hydrochloride) — Helsinn Birex Pharmaceuticals Ltd.
Aloxi (palonosetron hydrochloride) has been authorised in the EU for use related to vomiting and cancer indications.
-
CLINICAL_TRIALS trial_result · 2022-12-28Clinical Trial Update: Scopolamine Patch and Acupressure Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean Section [Phase 4]
Phase 4 trial evaluating scopolamine patch and acupressure at P6 for reducing nausea and vomiting during cesarean section; results posted in…
-
FDA approval · 2022-07-14FDA Approved: PROCHLORPERAZINE EDISYLATE — Original Application (Eugia US LLC)
FDA approves the original application for Prochlorperazine edisylate (generic) by Eugia US LLC.
-
EMA withdrawal · 2022-04-08EMA Withdrawn: Palonosetron Hospira (palonosetron hydrochloride) — Pfizer Europe MA EEIG
Palonosetron Hospira (palonosetron hydrochloride) has been withdrawn in the EMA system.
-
FDA approval · 2022-03-15FDA Approved: ONDANSETRON — Supplemental Application (Hospira, Inc.)
FDA approves Hospira, Inc.'s supplemental application for ondansetron, authorizing changes to the approved product.
-
CLINICAL_TRIALS trial_result · 2022-01-21Clinical Trial Update: The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs [Phase 2]
Phase 2 trial update on optimizing antiemetic regimen for radiotherapy-induced nausea and vomiting in locally advanced head and neck squamou…
-
FDA approval · 2021-09-28FDA Approved: PROCHLORPERAZINE EDISYLATE — Original Application (Cosette Pharmaceuticals, Inc.)
FDA approves Cosette Pharmaceuticals' prochlorperazine edisylate as an original generic application for use as an antiemetic.
-
FDA approval · 2021-07-12FDA Approved: PROMETHAZINE HYDROCHLORIDE — Original Application (QUAGEN PHARMACEUTICALS LLC)
FDA approved promethazine hydrochloride under an original ANDA for Quagen Pharmaceuticals LLC.
-
FDA approval · 2021-04-22FDA Approved: PROCHLORPERAZINE EDISYLATE — Original Application (Caplin Steriles Limited)
FDA approved the original application for PROCHLORPERAZINE EDISYLATE (Caplin Steriles Limited), a prochlorperazine edisylate antiemetic prod…